Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.74 |
| ▸ | DRD3 | P35462 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | GHSR | Q92847 | 2/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | HTR3A | P46098 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11745535 | 0.94 | OPRK1 (0.72) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11578252 | 0.94 | OPRK1 (0.72) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11579759 | 0.91 | OPRK1 (0.72) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11578948 | 0.90 | OPRK1 (0.71) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11577333 | 0.90 | TP53 (0.64) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11576688 | 0.89 | OPRK1 (0.59) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Elfazepam SCHEMBL1003682 | 0.89 | OPRK1 (0.60) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11750221 | 0.89 | OPRK1 (0.69) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11580468 | 0.87 | OPRK1 (0.70) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11578284 | 0.87 | OPRK1 (0.67) | OPRK1DRD3KCNH2GHSRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109006609-A | A kind of high-quality three-dimensional interaction breeding method of cray ecology | 黎建波 | 2018-12-18 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4010154-A | Benzodiazepinones | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-03-01 | — | — | US | claimed |
| US-3932637-A | 1-ALKYLSULFONYLALKYL-1,4-BENZODIAZEPINONES | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-01-13 | — | — | US | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2025-11-25 | — | — | US | disclosed |
| US-20250281535-A1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-09-11 | — | — | US | disclosed |
| US-4675174-A | Veterinary dispenser delivering beneficial agent by gas power generated in situ | ALZA CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
| US-4624945-A | Dispensing system with means for increasing delivery of beneficial agent from the system | ALZA CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| US-4612186-A | Method for establishing blood levels of biocide in animals | ALZA CORPORATION (US) | 1986-09-16 | — | — | US | disclosed |
| US-4251506-A | Controlled-release compositions for administration of therapeutic agents to ruminants | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1981-02-17 | — | — | US | disclosed |
| US-4079053-A | Benzodiazepine derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-03-14 | — | — | US | disclosed |
| US-4010154-A | Benzodiazepinones | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | OPRK1 3689/4885DRD3 2949/4885KCNH2 2347/4885 |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | OPRK1 13/4885DRD3 1215/4885KCNH2 3831/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | OPRK1 3285/4885DRD3 2318/4885KCNH2 1946/4885 |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | MAOB, MAOA, HTR2B | OPRK1 7/4885DRD3 691/4885KCNH2 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.